

16

# GOODMAN & GILMAN'S The PHARMACOLOGICAL BASIS OF THERAPEUTICS

Tenth Edition

McGraw-Hill  
MEDICAL PUBLISHING DIVISION

New York      Chicago      San Francisco      Lisbon      London      Madrid      Mexico City  
Milan      New Delhi      San Juan      Seoul      Singapore      Sydney      Toronto

BEST AVAILABLE COPY

## EDITORS

**Joel G. Hardman, Ph.D.**

Professor of Pharmacology, Emeritus  
Vanderbilt University Medical Center  
Nashville, Tennessee

**Lee E. Limbird, Ph.D.**

Professor of Pharmacology  
Associate Vice Chancellor for Research  
Vanderbilt University Medical Center  
Nashville, Tennessee

## CONSULTING EDITOR

**Alfred Goodman Gilman, M.D., Ph.D., D.Sc. (Hon.)**

Raymond and Ellen Willie Distinguished Chair in Molecular Neuropharmacology  
Regental Professor and Chairman, Department of Pharmacology  
University of Texas Southwestern Medical Center  
Dallas, Texas

**McGraw-Hill**

A Division of The McGraw-Hill Companies

**Goodman and Gilman's THE PHARMACOLOGICAL BASIS OF THERAPEUTICS. 10/e**

Copyright © 2001, 1996, 1990, 1985, 1980, 1975, 1970, 1965, 1955, 1941 by *The McGraw-Hill Companies, Inc.* All rights reserved. Printed in the United States of America. Except as permitted under the United States Copyright Act of 1976, no part of this publication may be reproduced or distributed in any form or by any means, or stored in a data base or retrieval system, without the prior written permission of the publisher.

1234567890 DOWDOW 0987654321

ISBN 0-07-135469-7

This book was set in Times Roman by York Graphic Services, Inc. The editors were Martin J. Wonsiewicz and John M. Morris; the production supervisor was Philip Galea; and the cover designer was Marsha Cohen/Parallelogram. The index was prepared by Irving Condé Tullar and Coughlin Indexing Services, Inc.  
R.R. Donnelley and Sons Company was printer and binder.

This book is printed on acid-free paper.

**Library of Congress Cataloging-in-Publication Data**

Goodman and Gilman's the pharmacological basis of therapeutics.—10th ed. / [edited by]  
Joel G. Hardman, Lee B. Limbird, Alfred Goodman Gilman.

p. ; cm.

Includes bibliographical references and index.

ISBN 0-07-135469-7

I. Pharmacology. 2. Chemotherapy. I. Title: Pharmacological basis of therapeutics.  
II. Goodman, Louis Sanford III. Gilman, Alfred IV. Hardman, Joel G.  
V. Limbird, Lee E. VI. Gilman, Alfred Goodman  
[DNLM: 1. Pharmacology. 2. Drug Therapy. QV 4 G6532 2002]

RM300 G644 2001

615.7—dc21

2001030728

INTERNATIONAL EDITION ISBN 0-07-112432-2  
Copyright © 2001. Exclusive rights by *The McGraw-Hill Companies, Inc.* for manufacture and export.  
This book cannot be re-exported from the country to which it is consigned by McGraw-Hill. The  
International Edition is not available in North America.

**BEST AVAILABLE**

tone is low (Marshall *et al.*, 1987; Honel and Lands, 1982). Further, acetaminophen does not inhibit neutrophil activation as do other NSAIDs (Abramson and Weissmann, 1989).

Single or repeated therapeutic doses of acetaminophen have no effect on the cardiovascular and respiratory systems. Acid-base changes do not occur, nor does the drug produce the gastro-irritation, erosion, or bleeding that may occur after administration of salicylates. Acetaminophen has no effects on platelets, bleeding time, or the excretion of uric acid.

**Pharmacokinetics and Metabolism.** Acetaminophen is rapidly and almost completely absorbed from the gastrointestinal tract. The concentration in plasma reaches a peak in 30 to 60 minutes, and the half-life in plasma is about 2 hours after therapeutic doses. Acetaminophen is relatively uniformly distributed throughout most body fluids. Binding of the drug to plasma proteins is variable; only 20% to 50% may be bound at the concentrations encountered during acute intoxication. After therapeutic doses, 90% to 100% of the drug may be recovered in the urine within the first day, primarily after hepatic conjugation with glucuronic acid (about 60%), sulfuric acid (about 35%), or cysteine (about 3%); small amounts of hydroxylated and deacetylated metabolites also have been detected. Children have less capacity for glucuronidation of the drug than do adults. A small proportion of acetaminophen undergoes cytochrome P450-mediated N-hydroxylation to form N-acetyl-benzoquinonimine, a highly reactive intermediate. This metabolite normally reacts with sulfhydryl groups in glutathione. However, after ingestion of large doses of acetaminophen, the metabolite is formed in amounts sufficient to deplete hepatic glutathione (see below).

**Therapeutic Uses.** Acetaminophen is a suitable substitute for aspirin for analgesic or antipyretic uses; it is particularly valuable for patients in whom aspirin is contraindicated (e.g., those with peptic ulcer) or when the prolongation of bleeding time caused by aspirin would be a disadvantage. The conventional oral dose of acetaminophen is 325 to 1000 mg (650 mg rectally); the total daily dose should not exceed 4000 mg. For children, the single dose is 40 to 480 mg, depending upon age and weight; no more than five doses should be administered in 24 hours. A dose of 10 mg/kg also may be used.

**Toxic Effects.** In recommended therapeutic dosage, acetaminophen usually is well tolerated. Skin rash and other allergic reactions occur occasionally. The rash is usually erythematous or urticarial, but sometimes it is more serious and may be accompanied by drug fever and mucosal lesions. Patients who show hypersensitivity reactions to the salicylates only rarely exhibit sensitivity to acetaminophen. In a few isolated cases, the use of acetaminophen has been associated with neutropenia, thrombocytopenia, and pancytopenia.

The most serious adverse effect of acute overdosage of acetaminophen is a dose-dependent, potentially fatal hepatic necrosis (see Thomas, 1993). Renal tubular necrosis and hypoglycemic coma also may occur. The mechanism by which overdosage with acetaminophen leads to hepatocellular injury and death involves its conversion to a toxic reactive metabolite (see also Chapter 4). Minor pathways of acetaminophen elimination are via conjugation with glucuronic acid and sulfate. The major pathway of metabolism is via cytochrome P450s to the intermediate, N-acetyl-*para*-benzoquinonimine, which is very elec-

trophilic. Under normal circumstances, this intermediate is inactivated by conjugation with glutathione (GSH) and then metabolized to a mercapturic acid and excreted into the urine. However, in the setting of acetaminophen overdose, hepatic cellular levels of GSH become depleted. Two consequences result as a result of depletion of GSH. Since GSH is an important antioxidant defense, hepatocytes are rendered highly susceptible to oxidant injury. Depletion of GSH also allows the intermediate to bind covalently to cell macromolecules, leading to dysfunction of enzymatic systems.

**Hepatotoxicity.** In adults, hepatotoxicity may occur after ingestion of a single dose of 10 to 15 g (150 to 250 mg/kg) of acetaminophen; doses of 20 to 25 g or more are potentially fatal. Alcoholics can have hepatotoxicity with much lower doses, even with doses in the therapeutic range. The mechanism of this effect is discussed above (see also Chapter 4). Symptoms that occur during the first 2 days of acute poisoning by acetaminophen may not reflect the potential seriousness of the hepatic damage. Nausea, vomiting, anorexia, diaphoresis, and abdominal pain occur during the initial 24 hours and may persist for 1 to 2 weeks or more. Clinical indications of hepatic damage may manifest within 2 to 4 days of ingestion of toxic doses. Transaminases are elevated (sometimes markedly), and the concentration of bilirubin in plasma may be increased. In addition, the prothrombin time is prolonged. Perhaps the most tragic aspect of acetaminophen poisoning is that patients poisoned patients who do not receive specific treatment may have severe liver damage; of these, 10% to 20% eventually develop hepatic failure. Acute renal failure also occurs in some patients. Biopsy of the liver reveals centrilobular necrosis with sparing of the periportal area. In nonfatal cases, the hepatic lesions are reversible over a period of weeks or months.

Severe liver damage (with levels of aspartate aminotransferase activity in excess of 1000 IU per liter of plasma) occurs in 90% of patients with plasma concentrations of acetaminophen greater than 300 µg/ml at 4 hours or 45 µg/ml at 15 hours after the ingestion of the drug. Minimal hepatic damage is anticipated when the drug concentration is less than 120 µg/ml at 4 hours or 30 µg/ml at 12 hours after ingestion. The potential severity of hepatic necrosis also can be predicted from the half-life of acetaminophen observed in the patient; half-lives greater than 4 hours imply that necrosis will occur, while half-lives greater than 12 hours suggest that hepatic coma is likely. A nomogram provided in Figure 27-2 relates the plasma level of acetaminophen and time after ingestion to the predicted severity of liver injury (see Rumack *et al.*, 1981).

Early diagnosis is vital in the treatment of overdosage with acetaminophen, and methods are available for the rapid determination of concentrations of the drug in plasma. However, this should not be delayed while awaiting laboratory results. The history suggests a significant overdosage. Vigorous supportive therapy is essential when intoxication is severe. Gastric lavage should be performed in all cases, preferably within 4 hours of the ingestion.

The principal antidotal treatment is the administration of sulfhydryl compounds, which probably act, in part, by replacing hepatic stores of glutathione. *N*-acetylcysteine (MUCON, MUCOSIL) is effective when given orally or intravenously. Intravenous form is available in Europe, where it is considered the treatment of choice. When given orally, the *N*-acetylcysteine solution (which has a foul smell and taste) is diluted with

Table A-II-1  
PHARMACOKINETIC DATA

AVAILABILITY (oral) (%)	URINARY EXCRETION (%)	BOUND IN PLASMA (%)	CLEARANCE (ml·min <sup>-1</sup> ·kg <sup>-1</sup> )	vol. dist. (liters/kg)	HALF-LIFE (hours)	PEAK TIME (hours)	PEAK CONCENTRATIONS
83 (63-110)	1 (0-4)	—	12.8 (9.3-17.5)	0.84 (0.68-1.03)	1.0 (0.8-1.3)	Tab: 0.53 (0.4-1.1) <sup>b</sup> Sot: 0.5 (0.5-0.6) <sup>b</sup>	Tab: 2.6 (2.3-2.9) μg/ml <sup>b</sup> Sot: 2.9 (2.5-3.4) μg/ml <sup>b</sup>

<sup>a</sup>Data from male subjects with HIV infection. Values are geometric means and 95% CI. Metabolized by ADH, UGT, and other enzymes.

<sup>b</sup>AC<sub>max</sub> and T<sub>max</sub> (geometric mean and 95% CI) following a 300-mg oral tablet (Tab) or solution (Sot).

Reference: Barry, M., Malekby, F., Merry, C., Gibbons, S., and Back, D. Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection. *Clin. Pharmacokinet.* 1995, 30:289-304.

Chidick, G.P., Gilchrist, C., McDonald, J.A., Lam, Y., Edwards, K.D., Prince, W.T., and Schin, D.S. Absolut: absolute bioavailability, bioequivalence of three oral formulations, and effect of food. *Pharmacoepiogr.* 1999, 10:933-942.

ABACAVIR: (Chapter 51)

AVAILABILITY (oral) (%)	URINARY EXCRETION (%)	BOUND IN PLASMA (%)	CLEARANCE (ml·min <sup>-1</sup> ·kg <sup>-1</sup> )	vol. dist. (liters/kg)	HALF-LIFE (hours)	PEAK TIME (hours)	PEAK CONCENTRATIONS
83 (63-110)	1 (0-4)	—	12.8 (9.3-17.5)	0.84 (0.68-1.03)	1.0 (0.8-1.3)	Tab: 0.53 (0.4-1.1) <sup>b</sup> Sot: 0.5 (0.5-0.6) <sup>b</sup>	Tab: 2.6 (2.3-2.9) μg/ml <sup>b</sup> Sot: 2.9 (2.5-3.4) μg/ml <sup>b</sup>

<sup>a</sup>Data from male subjects with HIV infection. Values are geometric means and 95% CI. Metabolized by ADH, UGT, and other enzymes.

<sup>b</sup>AC<sub>max</sub> and T<sub>max</sub> (geometric mean and 95% CI) following a 300-mg oral tablet (Tab) or solution (Sot).

Reference: Barry, M., Malekby, F., Merry, C., Gibbons, S., and Back, D. Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection. *Clin. Pharmacokinet.* 1995, 30:289-304.

Chidick, G.P., Gilchrist, C., McDonald, J.A., Lam, Y., Edwards, K.D., Prince, W.T., and Schin, D.S. Absolut: absolute bioavailability, bioequivalence of three oral formulations, and effect of food. *Pharmacoepiogr.* 1999, 10:933-942.

ACETAMINOPHEN (Chapter 27)

AVAILABILITY (oral) (%)	URINARY EXCRETION (%)	BOUND IN PLASMA (%)	CLEARANCE (ml·min <sup>-1</sup> ·kg <sup>-1</sup> )	vol. dist. (liters/kg)	HALF-LIFE (hours)	PEAK TIME (hours)	PEAK CONCENTRATIONS
88 ± 15	3 ± 1 ↔ Child	<20	5.0 ± 1.4 <sup>b</sup>	0.95 ± 0.12 <sup>b</sup>	2.0 ± 0.4 ↔ Aged, Hepf Lth, Hth, Child ↑ Obes, Hth, Preg	0.33-1.4 <sup>d</sup> ↔ RD, Obes, Child ↑ Noo, Hepf Hth, Preg	20 μg/ml <sup>b</sup>

<sup>a</sup>Values reported are for a linear kinetic model for doses less than 2 g; drug exhibits nonlinearity dependent on liver above this dose.

Assuming a 70-kg body weight, reported range, 65 to 72 kg.

<sup>b</sup>Acetaminophen-induced hepatic damage or acute viral hepatitis.

<sup>c</sup>Absorption rate, but not extent, depends on gastric emptying; hence, slowed after food as well as in some disease states and concomitant with drugs that cause hypotension.

<sup>d</sup>Mean concentration following a 20-mg/kg oral dose. Hepatic toxicity associated with levels >300 ng/ml at 4 hours after an overdose.

DL-α-CETYLCARNITIDE (LAAM) (Chapter 23)

AVAILABILITY (oral) (%)	URINARY EXCRETION (%)	BOUND IN PLASMA (%)	CLEARANCE (ml·min <sup>-1</sup> ·kg <sup>-1</sup> )	vol. dist. (liters/kg)	HALF-LIFE (hours)	PEAK TIME (hours)	PEAK CONCENTRATIONS
47 ± 5	6	80	4.93 ± 0.58	7.0	1.85 ± 4.9 ↔ Aged, Ctr	1.26 ± 0.2 <sup>b</sup> NL: 3.9 ± 0.7 <sup>b</sup> DL: 31 ± 9.6 <sup>b</sup>	1.63 ± 8 ng/ml <sup>b</sup> NL: 4.4 ± 4 ng/ml <sup>b</sup> DL: 19 ± 1 ng/ml <sup>b</sup>

<sup>a</sup>Data from healthy adult male subjects. LAAM (C) is metabolized by cytochrome P450 (primarily CYP2A) to active metabolites, m-LAAM (NL) and dimer-LAAM (DL).

<sup>b</sup>Following a single 40-mg oral dose.

Reference: Kalka, R.P., Chenevill, R.N., and Jumaral, C.E. Simultaneous determination of acetylcarnitide and its active biotransformation products in human biofluids. *J. Chromatogr.* 1975, 105: 267-288.

Welch, S.L., Johnson, R.E., Cone, E.J., and Hitchens, G.E. Jumaran and oral L-α-cetyl carnitide: pharmacodynamics and pharmacokinetics in humans. *J. Pharmacol. Exp. Ther.* 1998, 285:71-82.

DL-α-CETYLCARNITIDE (LAAM) (Chapter 27, 55)

AVAILABILITY (oral) (%)	URINARY EXCRETION (%)	BOUND IN PLASMA (%)	CLEARANCE (ml·min <sup>-1</sup> ·kg <sup>-1</sup> )	vol. dist. (liters/kg)	HALF-LIFE (hours)	PEAK TIME (hours)	PEAK CONCENTRATIONS
68 ± 3	1.4 ± 1.2 ↔ Aged, Ctr	49 ↔ RD	9.3 ± 1.1 ↔ Aged, Ctr	0.15 ± 0.03 ↔ H <sub>2</sub> P	0.25 ± 0.03 ↔ Aged, Ctr	0.39 ± 0.21 <sup>b</sup> ↔ H <sub>2</sub> P	24 ± 4 μg/ml <sup>b</sup>

<sup>a</sup>Values given are for unchanged parent drug. Acetyl carnitide is converted to salicylic acid during metabolism (C) and its metabolites (NL and DL) are dose-dependent half-life values between 2 hours and 10 hours. Data in 13 patients with chronic pain.

Reference: Roberts, M.S., Rumble, R.H., Warvinobuk, S., Thomas, D., and Brooks, P.M. Pharmacokinetics of aspirin and salicylic acid in elderly subjects and in patients with alcoholic liver disease. *Eur. J. Clin. Pharmacol.* 1992, 45:253-261.




Figure 27-3. Structural formulas of antiinflammatory propionic acid derivatives.

With this drug is greater. It is available for sale without a prescription in the United States. Naproxen has a longer half-life than most of the other structurally and functionally similar agents, making twice-daily administration of it feasible. This drug also is available without a prescription in the United States. Oxaprozin also has a long half-life and can be given once daily. The structural formulas of these drugs are shown in Figure 27-3.

**Pharmacological Properties.** The pharmacodynamic properties of the propionic acid derivatives do not differ significantly. All are effective cyclooxygenase inhibitors, although there is considerable variation in their potency. For example, naproxen is approximately 20 times more potent than aspirin, while ibuprofen, fenoprofen, and aspirin are roughly equipotent as cyclooxygenase inhibitors. All of these agents alter platelet function and prolong bleeding time, and it should be assumed that any patient who is intolerant of aspirin also will experience a severe reaction after administration of one of these drugs. Some of the propionic acid derivatives have prominent inhibitory effects on leukocyte function; naproxen is particularly potent in this regard. While the compounds do vary in potency, this is not of obvious clinical significance. All are effective antiinflammatory agents in various experimental animal models of inflammation; all have useful antiinflammatory, analgesic, and antipyretic activities in human beings. Although all of these compounds can cause gastric toxicity in patients, these are usually less severe than with aspirin.

It is difficult to find data on which to base a rational choice among the members of the propionic acid derivatives, if in fact one can be made. However, in relatively small clinical studies that compared the activity of several members of this group, patients preferred naproxen in terms of analgesia and relief of morning stiffness (see

Huskisson, in Symposium, 1983a; Hart and Huskisson, 1984). With regard to side effects, naproxen was the best tolerated, followed by ibuprofen and fenoprofen. There was considerable interpatient variation in the preference for a single drug and also between the designations of the best and the worst drug. Unfortunately, it is probably impossible to predict *a priori* which drug will be most suitable for any given individual. Nevertheless, more than 50% of patients with rheumatoid arthritis probably will achieve adequate symptomatic relief from the use of one or another of the propionic acid derivatives, and many clinicians favor their use instead of aspirin in such patients.

**Drug Interactions.** The potential adverse drug interactions of particular concern with propionic acid derivatives result from their high degree of binding to albumin in plasma. However, the propionic acid derivatives do not alter the effects of the oral hypoglycemic drugs or warfarin. Nevertheless, the physician should be prepared to adjust the dosage of warfarin because these drugs impair platelet function and may cause gastrointestinal lesions.

#### Ibuprofen

Ibuprofen is supplied as tablets containing 200 to 800 mg; the 200-mg tablets (ADVIL, NUPRIN, others) are available without a prescription.

For rheumatoid arthritis and osteoarthritis, daily doses up to 3200 mg in divided portions may be given, although the usual total dose is 1200 to 1800 mg. It also may be possible to reduce the dosage for maintenance purposes. For mild to moderate pain, especially that of primary dysmenorrhea, the usual dosage is 400 mg every 4 to 6 hours as needed. The drug may be given with milk or food to minimize gastrointestinal side effects. Ibuprofen has been discussed in detail by Katz (1979) and by Adams and Buckler (in Symposium, 1983a).

**Pharmacokinetics and Metabolism.** Ibuprofen is rapidly absorbed after oral administration, and peak concentration

Table A-II-1  
PHARMACOKINETIC DATA (Continued)

AVAILABILITY (oral)	URINARY EXCRETION (%)	BOUND IN PLASMA (%)	CLEARANCE (ml·min <sup>-1</sup> ·kg <sup>-1</sup> )	VOL. DST. (liters)	HALF-LIFE (hours)	PEAK TIME (hours)	PEAK CONCENTRATIONS
Oral: 42 ± 23 SC: ~80	6	7.1	14.6 ± 7.6	2.90 ± 1.31 <sup>b</sup>	2.4 ± 0.6	IV: <sup>c</sup>	IV: 242 ng/ml <sup>c</sup> Oral: 11.8 ± 2.6 ng/ml <sup>c</sup>
					Oral: 1.1 ± 0.2 <sup>c</sup>		

<sup>a</sup>Data from healthy male subjects. Extensively metabolized. The principal metabolite, 3-glucuronide, contributes to much higher (27-46%) levels than parent drug, and may contribute to some side effects (not antinociceptive).

<sup>b</sup>Never reported.

<sup>c</sup>Following a single 2-mg IV (bolus, sample at 3 minutes) or 4-mg oral dose.

#### HYDROMORPHONE (Chapter 23)

AVAILABILITY (oral)	URINARY EXCRETION (%)	BOUND IN PLASMA (%)	CLEARANCE (ml·min <sup>-1</sup> ·kg <sup>-1</sup> )	VOL. DST. (liters)	HALF-LIFE (hours)	PEAK TIME (hours)	PEAK CONCENTRATIONS
Oral: 42 ± 23 SC: ~80	6	7.1	14.6 ± 7.6	2.90 ± 1.31 <sup>b</sup>	2.4 ± 0.6	IV: <sup>c</sup>	IV: 242 ng/ml <sup>c</sup> Oral: 11.8 ± 2.6 ng/ml <sup>c</sup>

Reference: Hagen, N., Thiffault, M.D., Dhaliwal, H.S., Bahad, N., Mancayi, Z., and Darke, A.C. Study-site pharmacokinetics of hydromorphone and hydromorphone-β-glucuronide in cancer patients after immediate and controlled-release hydromorphone. *J. Clin. Pharmacol.* 1995; 35:37-44.  
Modlin, D.E., Krest, J.H., Murray-Pearson, N., and Bruggeillen, A.J. Comparison of continuous subcutaneous and intravenous hydromorphone infusions for management of cancer pain. *Lancet* 1991; 337:465-468.  
Panzica, P.V., Ritschel, W.A., Coffie, D.E., Gregg, R.V., and Deacon, D.R. Pharmacokinetics of hydromorphone after intravenous, peritoneal and rectal administration to human subjects. *Biopharm. Drug Dispos.* 1988; 9:183-199.

#### HYDROXYUREA<sup>a</sup> (Chapter 52)

AVAILABILITY (oral)	URINARY EXCRETION (%)	BOUND IN PLASMA (%)	CLEARANCE (ml·min <sup>-1</sup> ·kg <sup>-1</sup> )	VOL. DST. (liters)	HALF-LIFE (hours)	PEAK TIME (hours)	PEAK CONCENTRATIONS
108 ± 18 (79-108)	35.8 ± 14.2	Negligible	7.2 ± 1.7 ml·min <sup>-1</sup> (ml <sup>2</sup> ) <sup>-1</sup> (36.2-72.3)	19.7 ± 4.6 l <sup>-1</sup>	3.4 ± 0.7 (2.8-4.5)	IV: 0.5 <sup>c</sup> Oral: 1.2 ± 1.2 <sup>c</sup>	IV: 1017 ± 371 μM <sup>c</sup> Oral: 794 ± 241 μM <sup>c</sup>

<sup>a</sup>Data from male and female patients treated for solid tumors. A range of mean values from multiple studies is shown in parentheses.

<sup>b</sup>Plasma elimination of hydroxyurea is thought to exhibit saturable kinetics through a 10- to 10- to 10-mg dose range.

<sup>c</sup>Following a single 2-g IV bolus intravenous infusion or oral dose.

#### IBUPROFEN (Chapter 27)

AVAILABILITY (oral)	URINARY EXCRETION (%)	BOUND IN PLASMA (%)	CLEARANCE (ml·min <sup>-1</sup> ·kg <sup>-1</sup> )	VOL. DST. (liters)	HALF-LIFE (hours)	PEAK TIME (hours)	PEAK CONCENTRATIONS	
80	<1	>95 <sup>b</sup>	0.75 ± 0.29 <sup>c</sup>	0.15 ± 0.02 <sup>c</sup>	2 ± 0.5 <sup>b</sup>	RA, CF, Child ↔ CF ↔ Child, RA ↑ Cir	1.6 ± 0.3 <sup>c</sup>	61.1 ± 15 μg/ml <sup>c</sup>

<sup>a</sup>Reactive isomer. Kinetic parameters for this active S(+)-enantiomer do not differ from those for the inactive R(-)-enantiomer when administered separately. 61 ± 6% of the R(-)-enantiomer undergoes conversion to the active isomer.

<sup>b</sup>Unbound fraction of S(+)-ibuprofen (0.17 ± 0.20%) is significantly greater than that of R(-)-ibuprofen (0.05 ± 0.05%). Binding of each enantiomer is concentration dependent and is influenced by the presence of the optical antipode, leading to nonlinear elimination kinetics.

<sup>c</sup>CF and V/F reported.

<sup>d</sup>Following a single 800-mg dose of racemic. A level of 10 ng/ml provides analgesics in female children.

<sup>e</sup>Following a single 800-mg dose of racemic. A level of 10 ng/ml provides analgesics in female children.

BEST AVAILABLE COPY

Reference: Lee, E.J., Williams, K., Dow, R., Graham, G., and Chapman, D. Stereoselective disposition of ibuprofen enantiomers in man. *Br. J. Clin. Pharmacol.* 1985; 30:609-614.  
Lockwood, O.F., Alter, K.S., Gilkeson, W.R., Birk, G.O., Hanrahan, T.M., Sonnen, G.L., and Wiggins, J.G. Pharmacokinetics of ibuprofen in man. I. Free and total measures relationships. *Clin. Pharmacol. Ther.* 1983; 34:57-103.